

REGULATOR INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR:8502250311 DOC.DATE: 85/02/19 NOTARIZED: NO DOCKET #
 FACIL:STN-50-528 Palo Verde Nuclear Station, Unit 1, Arizona Publi 05000528
 STN-50-529 Palo Verde Nuclear Station, Unit 2, Arizona Publi 05000529
 STN-50-530 Palo Verde Nuclear Station, Unit 3, Arizona Publi 05000530
 AUTH.NAME: AUTHOR AFFILIATION
 TURLEY,K. Arizona Public Service Co.
 RECIP.NAME: RECIPIENT AFFILIATION
 KNIGHTON,G.W. Licensing Branch 3

SUBJECT: Advises that EE Van Brunt named executive vice president,
 effective 850228.

DISTRIBUTION CODE: M006D COPIES RECEIVED:LTR / ENCL 0 SIZE:-----
 TITLE: Changes of Personnel/Address.

NOTES:Standardized plant. 05000528
 OL:12/31/84
 Standardized plant. 05000529
 Standardized plant. 05000530

RECIPIENT		COPIES		RECIPIENT		COPIES	
ID.	CODE/NAME	LTTR	ENCL	ID	CODE/NAME	LTTR	ENCL
NRR/DL/ADL	12	1	1	NRR LB3 BC		1	0
NRR LB3 LA	04	1	1	LICITRA,E	01	1	1
INTERNAL: ACRS	13	1	1	ADM/LFMB		1	0
ADM/TIDC/DMB		1	1	ASLAP	10	1	1
ASLBP	09	1	1	ELD/HDS3	06	1	1
NRR/DL DIR		1	1	NRR/DL/SSPB RRA		1	1
NRR/DL/TAPMG		1	1	REG FILE	04	1	1
RGNS		1	1	RM/DDAMI/MIB	08	1	1
SECY/DSB		1	1				
EXTERNAL: LPDR	03	1	1	NRC PDR	02	1	1

1. *Pharmaceutical industry* – The pharmaceutical industry is a major player in the healthcare sector, responsible for the development, production, and distribution of drugs. It is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is often criticized for high prices and lack of transparency.

2. *Healthcare providers* – These include hospitals, clinics, and individual practitioners who deliver medical services. They are the primary point of contact for patients and are responsible for the diagnosis, treatment, and management of health conditions.

3. *Insurance companies* – Insurance companies play a crucial role in financing healthcare. They collect premiums from individuals and businesses and use the funds to pay for medical services. They often negotiate with providers and pharmaceutical companies to secure better rates.

4. *Government* – The government is a major stakeholder in the healthcare system, responsible for regulating the industry, providing funding for public health programs, and ensuring access to care for all citizens.

5. *Patients* – Patients are the ultimate beneficiaries of the healthcare system. They are responsible for seeking medical care, following treatment plans, and paying for services.

6. *Pharmaceutical manufacturers* – These are the companies that produce the drugs. They are responsible for the quality, safety, and efficacy of the products.

7. *Healthcare technology* – This includes medical devices, software, and other technologies used in healthcare. It is a rapidly growing sector that is transforming the way healthcare is delivered.

8. *Academic institutions* – Universities and research institutions are involved in the discovery and development of new drugs and medical technologies. They often collaborate with the pharmaceutical industry.

9. *Regulatory agencies* – These are government bodies responsible for enforcing regulations and standards in the healthcare industry. Examples include the FDA in the US and the EMA in Europe.

10. *Pharmaceutical distributors* – These companies are responsible for getting drugs from manufacturers to healthcare providers. They often have extensive distribution networks.

11. *Pharmaceutical sales and marketing* – This is the part of the pharmaceutical industry responsible for promoting and selling drugs. It often involves a lot of direct interaction with healthcare providers.

12. *Pharmaceutical research and development* – This is the part of the pharmaceutical industry responsible for discovering and developing new drugs. It is the most expensive and risky part of the industry.

13. *Pharmaceutical manufacturing* – This is the part of the pharmaceutical industry responsible for producing drugs. It involves a lot of complex machinery and processes.

14. *Pharmaceutical distribution* – This is the part of the pharmaceutical industry responsible for getting drugs from manufacturers to healthcare providers. It often involves a lot of logistics and transportation.

15. *Pharmaceutical sales and marketing* – This is the part of the pharmaceutical industry responsible for promoting and selling drugs. It often involves a lot of direct interaction with healthcare providers.

16. *Pharmaceutical research and development* – This is the part of the pharmaceutical industry responsible for discovering and developing new drugs. It is the most expensive and risky part of the industry.

17. *Pharmaceutical manufacturing* – This is the part of the pharmaceutical industry responsible for producing drugs. It involves a lot of complex machinery and processes.

18. *Pharmaceutical distribution* – This is the part of the pharmaceutical industry responsible for getting drugs from manufacturers to healthcare providers. It often involves a lot of logistics and transportation.

19. *Pharmaceutical sales and marketing* – This is the part of the pharmaceutical industry responsible for promoting and selling drugs. It often involves a lot of direct interaction with healthcare providers.

20. *Pharmaceutical research and development* – This is the part of the pharmaceutical industry responsible for discovering and developing new drugs. It is the most expensive and risky part of the industry.

[illegible]

Figure 1 is a line graph titled "Percentage of total population in the labor force by age group, 1960-1980". The vertical axis (Y-axis) is labeled "Percentage of total population in the labor force" and ranges from 0 to 100 in increments of 10. The horizontal axis (X-axis) is labeled "Year" and ranges from 1960 to 1980 in increments of 10. There are six data series representing different age groups: 15-24, 25-34, 35-44, 45-54, 55-64, and 65+. The 15-24 age group starts at approximately 25% in 1960 and declines steadily to about 15% by 1980. The 25-34 age group starts at approximately 15% in 1960 and rises slightly to about 20% by 1980. The 35-44 age group starts at approximately 10% in 1960 and rises slightly to about 15% by 1980. The 45-54 age group starts at approximately 5% in 1960 and rises slightly to about 10% by 1980. The 55-64 age group starts at approximately 2% in 1960 and rises slightly to about 5% by 1980. The 65+ age group starts at approximately 1% in 1960 and rises slightly to about 2% by 1980.

A black and white photograph of a large, multi-story building with a prominent central tower and many windows, likely a government or institutional building.

Arizona Public Service Company

P.O. BOX 21666 • PHOENIX, ARIZONA 85036

KEITH TURLEY
CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Director of Nuclear Reactor Regulation
Mr. George W. Knighton, Chief
Licensing Branch No. 3
Division of Licensing
U.S. Nuclear Regulatory Commission
Washington, D.C. 20555

February 19, 1985
ANPP-31921 KLT


Subject: Palo Verde Nuclear Generating Station (PVNGS)
Units 1, 2, and 3
ANPP Organization
Docket Nos. STN 50-528(License No. NPF-34)/529/530
File: 85-056-026; G.1.01.10

Dear Mr. Knighton:

This letter is provided to advise you that Mr. E. E. Van Brunt, Jr., has been named Executive Vice President for the Arizona Nuclear Power Project, effective March 1, 1985. Mr. Van Brunt will be fulfilling the position left by the retirement of Mr. Tom Woods on February 28, 1985. The responsibilities of the position of Executive Vice President, Arizona Nuclear Power Project will remain unchanged. Additionally, we are actively pursuing a replacement for the Vice President, Nuclear Production position previously held by Mr. Van Brunt.

Please contact me if you have any questions.

Very truly yours,



KLT/WFQ/mb

cc: J. B. Martin
R. P. Zimmerman
E. A. Licitra
A. C. Gehr
W. F. Quinn.
D. B. Karner
J. R. Bynum

8502250311 850219
PDR ADDOCK 05000528
H PDR

MOOB
1/0

